While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. (Operator Instructions) Today's conference is being recorded. Thank you. I ...

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

NVS' key drugs, Entresto, Cosentyx Kisqali and Pluvicto, are likely to have fueled its top and bottom-line performance in the fourth quarter.

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder ...

Several disease-modifying therapies (DMTs) can help change the disease course of MS. People with MS can also take other medications for symptoms, complications, and relapses. Multiple sclerosis ...

Potential New Drug Treatment for Multiple Sclerosis Dec. 8, 2023 — Pre-clinical studies using a small molecule drug have shown promise as a potential new treatment for multiple sclerosis ...

Injectable medications for multiple sclerosis (MS) are known as disease-modifying therapies (DMTs). This means they work by slowing or changing the progression of the condition. These are self ...